Market Place
Sourcing Support
For 2nd time in three months, Syndax wins FDA nod for a new drug
18 Nov 2024 //
FIERCE PHARMA
US FDA approves Syndax`s blood cancer drug
16 Nov 2024 //
REUTERS
Syndax stock slips after AML drug hits midstage trial goal
13 Nov 2024 //
FIERCE BIOTECH
Syndax strikes $350M funding deal with Royalty Pharma
06 Nov 2024 //
FIERCE PHARMA
Syndax Announces Revumenib Abstracts at ASH 2024
05 Nov 2024 //
PR NEWSWIRE
Syndax to Present AGAVE-201 Data on Niktimvo at ASH 2024
05 Nov 2024 //
PR NEWSWIRE
Syndax to Host ASH Investor Event Dec 9, 2024
05 Nov 2024 //
PR NEWSWIRE
Syndax Reports Q32024 Financial Results & Provides Business Update
05 Nov 2024 //
PR NEWSWIRE
Syndax & Royalty Pharma Enter $350M Niktimvo™ Royalty Deal
04 Nov 2024 //
PR NEWSWIRE
Syndax Announces Participation in November Investor Conferences
01 Nov 2024 //
PR NEWSWIRE
Syndax Reports Inducement Grants Under NASDAQ Rule 5635(c)(4)
01 Nov 2024 //
PR NEWSWIRE
Syndax To Announce Q3 2024 Results On Nov 5 2024
29 Oct 2024 //
PR NEWSWIRE
Syndax Reports Inducement Grants Under NASDAQ LR 5635(c)(4)
04 Oct 2024 //
PR NEWSWIRE
Incyte & Syndax Publish AGAVE-201 Trial Data on Axatilimab in GVHD
18 Sep 2024 //
PR NEWSWIRE
Syndax Pharmaceuticals Reports Inducement Grants Under Nasdaq Rule
06 Sep 2024 //
PR NEWSWIRE
Incyte, Syndax bag FDA approval for Niktimvo in graft-versus-host disease
15 Aug 2024 //
FIERCE PHARMA
Incyte And Syndax’s Niktimvo™ Approved By FDA For Chronic GVHD Treatment
14 Aug 2024 //
BUSINESSWIRE
Syndax Publishes AUGMENT-101 Trial Data On Revumenib In Leukemia
12 Aug 2024 //
PR NEWSWIRE
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule
05 Aug 2024 //
PR NEWSWIRE
Syndax Reports Q2 2024 Results And Provides Business Update
01 Aug 2024 //
PR NEWSWIRE
Syndax Announces PDUFA Date Extension For Revumenib In Acute Leukemia
29 Jul 2024 //
PR NEWSWIRE
Syndax To Report Q2 2024 Results On August 1
25 Jul 2024 //
PR NEWSWIRE
Syndax Pharmaceuticals Grants Inducement Awards Under NASDAQ Rule 5635(c)(4)
05 Jul 2024 //
PR NEWSWIRE
Actinium Presents Actimab-A Data At 2024 EHA Congress
17 Jun 2024 //
PR NEWSWIRE
Syndax Presents Updated Revumenib Data At EHA 2024
14 Jun 2024 //
PR NEWSWIRE
Syndax Plans Phase 1b Trial Of Revumenib In Relapsed/Refractory MSS CRC
06 Jun 2024 //
PR NEWSWIRE
Syndax: Participating At Goldman Sachs Healthcare Conference
05 Jun 2024 //
PR NEWSWIRE
Syndax Reports Nasdaq Employee Inducement Grants
03 Jun 2024 //
PR NEWSWIRE
Syndax Appoints Aleksandra Rizo To Board Of Directors
15 May 2024 //
PR NEWSWIRE
Syndax At BofA Securities Healthcare Conference 2024
09 May 2024 //
PR NEWSWIRE
Syndax Reports Q1 2024 Results, Clinical And Business Update
08 May 2024 //
PR NEWSWIRE
Syndax Reports Nasdaq Listing Rule Inducement Grants
03 May 2024 //
PR NEWSWIRE
Syndax Q1 2024 Results, Conference Call & Webcast On May 8
01 May 2024 //
PR NEWSWIRE
Syndax Announces Participation at the Stifel Virtual Targeted Oncology Forum
10 Apr 2024 //
PR NEWSWIRE
Syndax Presents Positive Data from Pivotal AUGMENT-101 Trial
08 Apr 2024 //
PR NEWSWIRE
Syndax Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
05 Apr 2024 //
PR NEWSWIRE
Syndax Completion of Enrollment in AUGMENT-101 Trial of Patients with r/r AML
28 Mar 2024 //
PR NEWSWIRE
Syndax FDA Priority Review of NDA for Revumenib Relapsed/Refractory KMT2Ar
26 Mar 2024 //
PR NEWSWIRE
Syndax Announces Appointment of Steven Closter as Chief Commercial Officer
18 Mar 2024 //
PR NEWSWIRE
Syndax Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
01 Mar 2024 //
PR NEWSWIRE
Syndax Pharma Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 2024 //
PR NEWSWIRE
Syndax Announces Participation at Two Upcoming Investor Conferences
26 Feb 2024 //
PR NEWSWIRE
Syndax to Announce Fourth Quarter and Year-end 2023 Financial Results
20 Feb 2024 //
PR NEWSWIRE
Syndax Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
02 Feb 2024 //
PR NEWSWIRE
Syndax Announces Participation at Two Upcoming Investor Conferences
01 Feb 2024 //
PR NEWSWIRE
Syndax Pharma Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
05 Jan 2024 //
PR NEWSWIRE
Syndax Highlights Recent Updates and Anticipated 2024 Milestones
02 Jan 2024 //
PR NEWSWIRE
Syndax Announces Presentation at 42nd Annual J.P. Morgan Healthcare Conference
02 Jan 2024 //
PR NEWSWIRE
Syndax Announces Closing of Public Offering of Common Stock
19 Dec 2023 //
PR NEWSWIRE
Syndax Announces Proposed $150 Million Public Offering of Common Stock
14 Dec 2023 //
PR NEWSWIRE
Syndax Announces Pricing of $200 Million Public Offering of Common Stock
14 Dec 2023 //
PR NEWSWIRE
Syndax Presents Data from AUGMENT-101 Trial of Revumenib in Acute Leukemia
12 Dec 2023 //
PR NEWSWIRE
Syndax Announces Positive Data for Revumenib in Patients with Acute Leukemias
11 Dec 2023 //
PRESS RELEASE
Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial
10 Dec 2023 //
BUSINESSWIRE
Syndax to Host Investor Event to Discuss Axatilimab and Revumenib Data
04 Dec 2023 //
PR NEWSWIRE
Syndax Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
01 Dec 2023 //
PR NEWSWIRE
Syndax Announces Data from Pivotal AUGMENT-101 Trial of Revumenib
21 Nov 2023 //
PR NEWSWIRE
Syndax Announces Participation at Stifel Healthcare Conference
07 Nov 2023 //
PR NEWSWIRE
Syndax Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
03 Nov 2023 //
PR NEWSWIRE
Syndax Announces Data Supporting Impressive Clinical Profile of Revumenib
02 Nov 2023 //
PR NEWSWIRE
